PEER-REVIEWED ARTICLES, ACADEMIC BOOK CHAPTERS, CONFERENCE PROCEEDINGS, PATENTS, and PATENT APPLICATIONS

 

PEER-REVIEWED ARTICLES

 

  1. Miller, M., Klyosov, A.A., Platt, D., Mayo, K. Using Pulse Field Gradient NMR diffusion measurements to define molecular weight distributions in glycan preparations. Carbohydrate Research, 344, 1205-1212 (2009)

 

  1. Miller, M., Nesmelova, I.V., Platt, D., Klyosov, A.A., Mayo, K. The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem. J. 421, 211-221 (2009).

 

  1. Miller, M.C., Klyosov, A., Mayo, K.H. The α-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology, 19, No. 9, 1034-1045 (2009).
  1. Tevyashova, A.N., Olsufyeva, E.N., Preobrazhenskaya, M.N., Klyosov, A.A., Zomer, E., Platt, D. New Conjugates of an Antitumor Antibiotics Doxorubicin with a Water-soluble Galactomannan: Synthesis and Biological Activity. Bioorganic Chemistry (Moscow, in Russian), v. 33, No. 1, pp. 1 - 8 (2007)
  2. Olsufyeva, E.N., Tevyashova, A.N., Trestchalin, I.D., Preobrazhenskaya, M.N., Platt, D., Klyosov, A.A. Synthesis and Antitumor Activity of New Galactose-Containing Derivatives of Doxorubicin. Carbohydrate Research, 338 (13), 1359-1367, 2003.
  3. Klyosov, A.A., Platt, D., Zomer, E. Preclinical Studies of Anticancer Efficacy of 5-Fluorouracil when Co-Administered with the 1,4-beta-D-Galactomannan. PRECLINICA, 1, 175-186, 2003.
  4. Miller, M.C., Ribeiro, J.P., Roldos, V., Martin-Santamaria, S., Canada, F.J., Nesmelova, I., Andre, S., Pang, M., Klyosov, A., Baum, L.G., Jimenez-Barbero, J., Gabius, H.-J., Mayo, K.H. Structural aspects of binding of alpha-linked digalactosides to human galectin-1. Glycobiology, 21, 1627-1641, 2011.

    8.   Miller, M.C., Klyosov, A.A., Mayo, K. H. Structural features for α-galactomannan binding to galectin-1. Glycobiology, 22, 543-551, 2012.

    9.   Klyosov, A.A., Dotsenko, G.S., Hinz, S.W., Sinitsyn, A.P. Structural features of beta-(1-->4)-D-galactomannans of plant origin as a probe for beta-(1-- >4)-mannanase polymer substrate specificity. Carbohydrate Research, 352, 65-69, 2012.

    10.   Traber, P.G., Chou, H., Zomer, E., Hong, F., Klyosov, A.A., Fiel, M.-I., Friedman, S.L. Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. PloS One, 8, No. 10, e75361, 2013.

    11.   Miller, M.C., Ippel, H., Suylen, D., Klyosov, A.A., Traber, P.G., Hackeng, T., Mayo, K.H. Binding of Polysaccharides to Human Galectin-3 at a Noncanonical Site in its Carbohydrate recognition domain ,   Glycobiology, 26, 88-99, 2016.

    12.   Stegmayr, J., Lepur, A., Kahl-Knutson, B., Aguilar-Moncayo, M., Klyosov, A.A., Field, R.A., Oredsson, S., Nilsson, U.J., Leffler, H. Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site ny Pectins and Galactomannans ,   J. Biol. Chem., 291, 13318-13334, 2016.

 

 

ACADEMIC BOOK CHAPTERS


In: GALECTINS (ed. Anatole Klyosov, Zbigniew Witczak, David Platt), John Wiley & Sons, 2008

    13.         Klyosov, A.A. Galectins and their functions in plain language. In: Galectins (ed. Anatole Klyosov, Zbigniew Witczak, David Platt), John Wiley & Sons, 2008, pp. 9-31.

In: CARBOHYDRATE DRUG DESIGN (ed. Anatole Klyosov, Zbigniew Witczak, David Platt), Oxford University Press, 2006

    14.          Klyosov, A.A. Carbohydrates and Drug Design. In: Carbohydrate Drug Design (Anatole A. Klyosov, Zbigniew J. Witczak, and David Platt, eds.), ACS Symposium  Series 932, American Chemical Society, Washington, DC, 2006, pp. 2 - 24.

    15.          Platt, D., Klyosov, A.A., Zomer, E. Development of a Polysaccharide as a Vehicle to Improve the Efficacy of Chemotherapeutics. In: Carbohydrate Drug Design (Anatole A.  Klyosov, Zbigniew J. Witczak, and David Platt, eds.), ACS Symposium Series 932, American Chemical Society, Washington, DC, 2006, pp. 49 - 66.

    16.          Klyosov, A.A., Zomer, E., Platt, D. DAVANAT and Colon Cancer: Preclinical and Clinical (Phase I) Studies. In: Carbohydrate Drug Design (Anatole A. Klyosov, Zbigniew J. Witczak, and David Platt, eds.), ACS Symposium Series 932, American Chemical Society, Washington, DC, 2006, pp. 67 - 104.

    17.          Klyosov, A.A., Tevyashova, A.N., Olsufyeva, E.N., Preobrazhenskaya, M.N., Zomer, E., Platt, D. Synthesis and Biological Activity of Doxo-Galactose and Doxo-Galactomannan, New Conjugates of Doxorubicin with D-Galactose and 1,4-beta-D-Galactomannan. In: Carbohydrate Drug Design (Anatole A. Klyosov, Zbigniew J. Witczak, and David Platt, eds.), ACS Symposium Series 932, American Chemical Society, Washington, DC, 2006, pp. 105 - 130.

In: GLYCOBIOLOGY AND DRUG DESIGN (ed. Anatole Klyosov), Oxford University Press, 2013

 

    18.           Klyosov, A.A. Carbohydrates and Drug Design. In: Glycobiology and Drug Design (Anatole A. Klyosov, ed.), ACS Symposium  Series 1102, American Chemical Society, Washington, DC, 2013, pp. 3 - 22.

 

    19.           Klyosov, A.A. Galectin-targeted Drug Design. In: Glycobiology and Drug Design (Anatole A. Klyosov, ed.), ACS Symposium  Series 1102, American Chemical Society, Washington, DC, 2013, pp. 25 - 66.

    20.          Zomer, E., Klyosov, A.A. Platt, D. Development of a Galactomannan Polysaccharide as a Vehicle to Improve the Efficacy of Chemotherapeutics. In: Glycobiology and Drug Design (Anatole A. Klyosov, ed.), ACS Symposium  Series 1102, American Chemical Society, Washington, DC, 2013, pp. 69 - 87.

    21.          Klyosov, A.A., Zomer, E., Platt, D. DAVANAT (GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies. In: Glycobiology and Drug Design (Anatole A. Klyosov, ed.), ACS Symposium  Series 1102, American Chemical Society, Washington, DC, 2013, pp. 89 - 130.

    22.          Tevyashova, A.N., Klyosov, A.A., Olsufyeva, E.N., Preobrazhenskaya, M.N., Zomer, E. Synthesis and Biological Activity of Galactomycin and DoxoDavanat, New Conjugates of Doxorubicin with D-Galactose and 1,4-beta-D-Galactomannan. In: Glycobiology and Drug Design (Anatole A. Klyosov, ed.) ACS Symposium  Series 1102, American Chemical Society, Washington, DC, 2013, pp. 131 - 154.

 

CONFERENCE PROCEEDINGS

    23.         Zalupski, M., Fuloria, J., Perez, R., Abubaker, Y., Nahum, K.D., Platt, D., Klyosov, A.A. Zomer, E. Pharmacokinetic translational study in advanced solid tumors of 5-FU with an admixture of a galactomannans derivative. In: Cancer Research, Tumor Markers, Clinical Oncology. The 35th Meeting of the International Society for Oncodevelopmental Biology and Medicine, ISOBM 2007. Tumor Biology. Abstract P6_4, p. 119. Karger (Basel-Freiburg-Paris-London-New York-Bangalore-Singapore-Tokyo-Sydney). 

    24.          Demotte, N., Wieers, G., Klyosov, A., van der Bruggen, P. Is it possible to correct the impaired function of human tumor-infiltrating lymphocytes? Keystone Symposium on Molecular and Cellular Biology. New Frontiers at the Interface of Immunity and Glycobiology, March 6-11, 2011. Lake Louise, AB, Canada. Abstract 23F11.

 

US and INTERNATIONAL PATENTS GRANTED

      25.        Klyosov, A., Platt, D. Methods and Compositions for Reducing Side Effects in Chemotherapeutic Treatments. US Patent No. 6,642,205, November 4, 2003.

      26.       Klyosov, A., Platt, D. Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity. US Patent No. 6,645,946, November 11, 2003.

      27.        Klyosov, A., Platt, D. Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity. US Patent No. 6,914,055, July 5, 2005.

      28.       Klyosov, A., Platt, D. Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity. US Patent No. 6,982,255, January 3, 2006.

      29.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. US Patent No. 7,012,068, March 14, 2006.

      30.        Platt, D., Klyosov, A. Selectively Depolymerized Galactomannan Polysaccharide. US Patent No. 7,893,252, February 22, 2011. http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7893252.PN.&OS=PN/7893252&RS=PN/7893252

      31.     Platt, D., Zomer, E., Klyosov, A.A.  Galactose-Pronged Polysaccharides in a Formulation for Antifibrotic Therapies.  US Patent No. 8,236,780, filed May 16, 2007, granted August 7, 2012.  

      32.     Platt, D., Zomer, E., Klyosov, A.A.  Galactose-Pronged Polysaccharides in a Formulation for Antifibrotic Therapies.  US Patent No. 8,367,638, filed December 21, 2011, granted February 5, 2013.  

      33.      Traber, P.G., Zomer, E., Klyosov, A.A. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty-liver disease. US Patent No. 8,658,787, filed September 14, 2012, granted February 25, 2014.

      34.      Platt, D., Zomer, E., Klyosov, A.A. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies. UA Patent No. 8,722,645, filed July 17, 2012, granted May 13, 2014.

      35.      Zomer, E., Traber, P.G., Klyosov, A.A., Chekhova, E. Compositions of novel carbohydrate drug for treatment of human diseases. US Patent No. 8,871,925, filed September 14, 2012, granted October 28, 2014.

      36.      Zomer, E., Traber, P.G., Klyosov, A.A., Chekhova, E. Compositions of novel carbohydrate drug for treatment of human diseases. US Patent No. 8,962,824, filed August 11, 2014, granted February 24, 2015.

      37.      Platt, D., Zomer, E., Klyosov, A.A. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies. US Patent No. 9,200,090, filed December 26, 2012, granted December 1, 2015.

      38.      Zomer, E., Traber, P.G., Klyosov, A.A., Chekhova, E. Compositions of novel carbohydrate drug for treatment of human diseases. US Patent No. 9,649,327, filed December 18, 2014, granted May 16, 2017.

      39.      Traber, P.G., Zomer, E., Klyosov, A.A. Galacto-rhamnogalacturonate compositions for the treatment of diseases accociated with elevated inducible nitric oxide synthase. US Patent No. 9,763,974, filed June 6, 2013, granted September 19, 2017.

      40.      Traber, P.G., Redmond, W.L., Zomer, E., Klyosov, A.A., Linch, S.N. Method for enhancing specific immunotherapies in cancer treatment. US Patent No. 9,872,909, filed September 17, 2013, granted January 23, 2018.

      41.      Zomer, E., Traber, P.G., Klyosov, A.A., Chekhova, E. Compositions of novel carbohydrate drug for treatment of human diseases. US Patent No. 9,974,802, filed April 4, 2017, granted May 22, 2018.

      42.        Platt, D., Klyosov, A. Co-administration of Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of Australia 272022B2, February 17, 2011. Terms of the Patent: 20 years from 7 September 2004.

      43.       Klyosov, A., Platt, D. Co-administration of Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of Japan, No. 4744782, May 20, 2011.

      44.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of EP, No. 1383516.

 

      45.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of BE, No. 1383516.

 

      46.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of CH, No. 1383516.

 

      47.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of DE, No. 1383516.

 

      48.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of DK, No. 1383516.

 

      49.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of ES, No. 1383516.

 

      50.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of FR, No. 1383516.

 

      51.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of GB, No. 1383516.

 

      52.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of IE, No. 1383516.

 

      53.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of LU, No. 1383516.

 

      54.       Klyosov, A., Platt, D. Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer. Patent of NL, No. 1383516.

 

   55.       Traber, P., Redmond, W., Zomer, E., Klyosov, A., Linch, S. Method for Enhancing Specific Immunotherapies in Cancer Treatment. US Patent No. 10,398,778, Granted September 3, 2019.

 

   56.       Platt, D., Zomer, E., Klyosov, A. Galactose-Pronged Polysaccharides in a Formulation for Antifibrotic Therapies. US Patent No. 10,744,154, Granted August 18, 2020.

 

   57.       Zomer, E., Traber, P., Klyosov, A., Chekhova, E. Composition of Novel Carbohydrate Drug for Treatment of Human Diseases. US Patent No. 10,799,525, Granted October 13, 2020.

 

  

US PATENT APPLICATIONS

 

      58.       Traber, P.G., Zomer E., Klyosov, A.A. Methods of Treatment for Non-Alcoholic Steatohepatitis (NASH). Provisional U.S. Patent Application, filed June 6, 2012, 61/656/288.

     59.        Klyosov, A.A. The Optimal Structural Signature for α-Galactomannan binding to Galectin-1. Provisional U.S. Patent Application, filed September 13, 2011, 61/534,024. 

    

 

INTERNATIONAL PATENT APPLICATIONS

 

60. Klyosov, A.A., Platt, D. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer. EPO 10184166.6

61. Klyosov, A.A., Platt, D. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer. EP 04783211.8

62. Platt, D., Klyosov, A. Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer. Australian Patent Application No. 2010257400. Austr. Ref. 19435PRO/BMN/tap, PRW ref. 89918.020603 (allowed)

63. Platt, D., Klyosov, A. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer. Israel 174121, filed September 8, 2003, allowed.

64. Klyosov, A.A., Platt, D. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of a cancer. Japanese Patent Application No. 2002-574987, Y/R: 089919.02180; O/R: IP2003-149/KI (Our Ref. 089918.021804)  

65. Platt, D., Zomer, E., Klyosov, A. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer. Brazil PI0413410-0, filing September 8, 2003.

66. Platt, D., Zomer, E., Klyosov, A.A. Compositions and Methods for Treating Metastatic Tumors Using Multivalent Ligand-Linked Carbohydrate Polymers.  JP 2007-504160

67. European Patent Application No. 02731178.6, EPO Ref.: RJS\JWK\19462-5EP(PCT); Our Ref. 89918.021803.

68. Methods for Reducing the Incidence of Chemotherapy-Induced Mucositis. PCT/US09/053115.

69. European Patent Application No. 10184166.6, EPO Ref.: RJS\JWK\19462-5EP-DIV; Our Ref. 89918.021803.